{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042342","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.953588+00:00","generated_at":"2026-05-24T10:09:58.647416+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari Therapeutics appoints Abizer Gaslightwala President and CEO; Samir Patel steps down effective April 14, 2025","bullets":["Abizer Gaslightwala appointed President and CEO effective ~April 21, 2025; prior SVP at Jazz Pharmaceuticals.","Annual base salary $475,000, target cash bonus of 50% base; time-based option for 1,100,000 ADS (4-yr vest).","Performance-based option for 600,000 ADS vests upon: ≥$15M financing or ≥$10M upfront ADC license by Dec 31, 2025.","Samir Patel steps down as CEO effective April 14, 2025, remains on Board; separation terms pending.","New CEO's employment includes non-compete on ADC-focused biopharma for 12 months post-employment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042342","json":"https://secwatch.observer/filing/0000950170-25-042342.json","markdown":"https://secwatch.observer/filing/0000950170-25-042342.md","text":"https://secwatch.observer/filing/0000950170-25-042342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025042342/0000950170-25-042342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025042342/aktx-20250314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:09:58.647416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}